About talazoparib tosylate eq to talazoparib free base
PARP inhibitor anticancer medicine
Used for
- Treats certain inherited BRCA-mutated, advanced breast cancers.
- Treats certain inherited HRR-gene-mutated, castration-resistant prostate cancers with enzalutamide.
Usual adult dose
Breast cancer: 1 mg by mouth once daily. Prostate cancer: 0.5 mg once daily with enzalutamide; doses may be reduced for kidney problems or side effects.
Common side effects
- Low blood cell counts, including anemia, neutropenia, and low platelets
- Tiredness
- Nausea or vomiting
- Hair loss or reduced appetite
Important warnings
- Can cause serious bone marrow suppression; blood counts need monitoring.
- Rarely causes myelodysplastic syndrome or acute myeloid leukemia.
- May harm an unborn baby; effective contraception is required during treatment.
- Capsules must be swallowed whole; do not open or dissolve.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and use effective contraception; follow product guidance after the final dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for at least one month after the final dose.
Interactions
- Strong P-glycoprotein inhibitors can increase talazoparib exposure.
- P-glycoprotein inducers may reduce exposure and effectiveness.
- Enzalutamide is used together with talazoparib for prostate cancer; it can increase exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.